Clinical Trial Search

Primary: Change From Baseline in Morning Pre-dose Trough FEV1 at Week 24 of Treatment (US/China Approach) — 120; 47; 60; -45 mL

Primary: Area Under the Concentration-time Curve of the BI 695501 in Plasma Over the Time Interval From 0 Extrapolated to Infinity (AUC0-∞) — 2740; 2390; 2050…

Primary: Number of Participants With Dose Limiting Toxicities (DLTs) — 0; 0; 0; 0 Participants

Primary: Change in Weight — 209; 205 pounds — p=.095

Primary: Change Task - Stop Signal Reaction Time — 233.8; 238.3; 213.6; 234.7 miliseconds — p=0.36

Primary: Percentage of Participants With Treatment Emergent Adverse Events (AEs), Serious Adverse Events (SAEs) and Deaths as a Measure of Safety and Tolerability of LCZ696…

Primary: Number of Participants Who Experienced One or More Adverse Events — 2; 3; 5; 2 Participants

Primary: Number of Participants With Clinically Significant Effects — 0; 0; 0; 0 participants

Primary: Number of Participants With Treatment Emergent Adverse Events — 24 Participants

Primary: Percentage of Participants With Composite Measure of Perinatal Death, Maternal Death, or Maternal Severe Complications Within 7 Days — 15.1; 15.3 percentage of…

Primary: % Surface Micro Hardness Recovery (SMHR; Comparison of 1150 Ppm Fluoride and 5% KNO3 Dentifrice Relative to a Fluoride Free Placebo Dentifrice to Enhance…

Primary: Number of Participants With Evaluator (Dermatologist) Global Assessment (EGA) Score for Well Tolerance of Product 14 Days Post-Procedure — 36; 38 Participants — p=0.3334

Primary: Overall Clinical Assessment of the Haemostatic Efficacy of Octafibrin in Treating the First Documented Bleeding Episode of Each Patient. — 19; 23; 5; 1 Participants

Primary: Frequency as Percentage of Sensor Usage — 37; 31; 28; 27 % of time

Primary: Glucagon Counterregulation to Hypoglycemia — 16.0; 16.5 pmol/l